# MiNK Therapeutics, Inc.: financial statements, quarterly

INKT · Nasdaq · CIK 1840229 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/inkt.md) · [Financials](/companies/inkt/financials.md) · [Filings](/companies/inkt/filings.md) · [Insiders](/companies/inkt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/inkt/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $k | [3,427](/filings/0000950170-24-127033.md) | [3,311 d](/filings/0000950170-25-041379.md) | [2,549](/filings/0000950170-25-072789.md) | [1,840](/filings/0000950170-25-108894.md) | [541](/filings/0001193125-25-282905.md) | [1,406 d](/filings/0001193125-26-134813.md) | [1,262](/filings/0001193125-26-226804.md) | [1,839](/filings/0001193125-26-349309.md) | [1,143](/filings/0001193125-25-282905.md) | [1,513 d](/filings/0001193125-26-134813.md) | [1,204](/filings/0001193125-26-226804.md) | [1,887](/filings/0001193125-26-349309.md) |
| Operating income | $k | [(5,224)](/filings/0000950170-24-127033.md) | [(5,500) d](/filings/0000950170-25-041379.md) | [(3,830)](/filings/0000950170-25-072789.md) | [(3,071)](/filings/0000950170-25-108894.md) | [(1,885)](/filings/0001193125-25-282905.md) | [(2,503) d](/filings/0001193125-26-134813.md) | [(2,701)](/filings/0001193125-26-226804.md) | [(4,052)](/filings/0001193125-26-349309.md) | [(3,184)](/filings/0001193125-25-282905.md) | [(2,705) d](/filings/0001193125-26-134813.md) | [(2,882)](/filings/0001193125-26-226804.md) | [(3,217)](/filings/0001193125-26-349309.md) |
| Interest expense | $k | not reported | not reported | [(10.0)](/filings/0000950170-25-072789.md) | [(26.0)](/filings/0000950170-25-108894.md) | [(28.0)](/filings/0001193125-25-282905.md) | [(30.0) d](/filings/0001193125-26-134813.md) | [(29.0)](/filings/0001193125-26-226804.md) | [(27.0)](/filings/0001193125-26-349309.md) | [(25.0)](/filings/0001193125-25-282905.md) | [(29.0) d](/filings/0001193125-26-134813.md) | [(4.0)](/filings/0001193125-26-226804.md) | [(2.0)](/filings/0001193125-26-349309.md) |
| Net income | $k | [(5,116)](/filings/0000950170-24-127033.md) | [(5,459) d](/filings/0000950170-25-041379.md) | [(3,813)](/filings/0001193125-25-282905.md) | [(2,702)](/filings/0001193125-25-282905.md) | [(1,807)](/filings/0001193125-25-282905.md) | [(2,463) d](/filings/0001193125-26-134813.md) | [(2,767)](/filings/0001193125-26-349309.md) | [(4,238)](/filings/0001193125-26-349309.md) | [(2,888)](/filings/0001193125-25-282905.md) | [(2,602) d](/filings/0001193125-26-134813.md) | [(2,742)](/filings/0001193125-26-349309.md) | [(3,128)](/filings/0001193125-26-349309.md) |
| Diluted EPS | $ per share | [(0.15)](/filings/0000950170-24-127033.md) | not reported | [(1.10)](/filings/0000950170-25-072789.md) | [(0.73)](/filings/0000950170-25-108894.md) | [(0.46)](/filings/0001193125-25-282905.md) | not reported | [(0.70)](/filings/0001193125-26-226804.md) | [(1.06)](/filings/0001193125-26-349309.md) | [(0.65)](/filings/0001193125-25-282905.md) | not reported | [(0.57)](/filings/0001193125-26-226804.md) | [(0.62)](/filings/0001193125-26-349309.md) |
| Basic EPS | $ per share | [(0.15)](/filings/0000950170-24-127033.md) | not reported | [(1.10)](/filings/0000950170-25-072789.md) | [(0.73)](/filings/0000950170-25-108894.md) | [(0.46)](/filings/0001193125-25-282905.md) | not reported | [(0.70)](/filings/0001193125-26-226804.md) | [(1.06)](/filings/0001193125-26-349309.md) | [(0.65)](/filings/0001193125-25-282905.md) | not reported | [(0.57)](/filings/0001193125-26-226804.md) | [(0.62)](/filings/0001193125-26-349309.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [6.4](/filings/0000950170-23-063851.md) | [3.4](/filings/0000950170-25-041379.md) | [5.8](/filings/0000950170-24-059081.md) | [9.3](/filings/0000950170-24-096142.md) | [6.3](/filings/0000950170-24-127033.md) | [4.6](/filings/0001193125-26-134813.md) | [3.2](/filings/0000950170-25-072789.md) | [1.7](/filings/0000950170-25-108894.md) | [9.5](/filings/0001193125-26-226804.md) | [13.4](/filings/0001193125-26-349309.md) | [9.5](/filings/0001193125-26-226804.md) | [8.8](/filings/0001193125-26-349309.md) |
| Current assets | $m | [6.5](/filings/0000950170-23-063851.md) | [3.6](/filings/0000950170-25-041379.md) | [6.0](/filings/0000950170-24-059081.md) | [9.5](/filings/0000950170-24-096142.md) | [6.6](/filings/0000950170-24-127033.md) | [5.0](/filings/0001193125-26-134813.md) | [3.6](/filings/0000950170-25-072789.md) | [2.0](/filings/0000950170-25-108894.md) | [14.5](/filings/0001193125-25-282905.md) | [13.8](/filings/0001193125-26-349309.md) | [10.0](/filings/0001193125-26-226804.md) | [9.3](/filings/0001193125-26-349309.md) |
| Total assets | $m | [7.5](/filings/0000950170-23-063851.md) | [4.6](/filings/0000950170-25-041379.md) | [6.9](/filings/0000950170-24-059081.md) | [10.3](/filings/0000950170-24-096142.md) | [7.4](/filings/0000950170-24-127033.md) | [5.7](/filings/0001193125-26-134813.md) | [4.3](/filings/0000950170-25-072789.md) | [2.5](/filings/0000950170-25-108894.md) | [15.0](/filings/0001193125-25-282905.md) | [14.2](/filings/0001193125-26-349309.md) | [10.4](/filings/0001193125-26-226804.md) | [9.6](/filings/0001193125-26-349309.md) |
| Current liabilities | $m | [10.4](/filings/0000950170-23-063851.md) | [11.4](/filings/0000950170-25-041379.md) | [11.1](/filings/0000950170-24-059081.md) | [10.1](/filings/0000950170-24-096142.md) | [7.4](/filings/0000950170-24-127033.md) | [7.0](/filings/0001193125-26-134813.md) | [12.1](/filings/0000950170-25-072789.md) | [13.2](/filings/0000950170-25-108894.md) | [13.4](/filings/0001193125-25-282905.md) | [13.0](/filings/0001193125-26-349309.md) | [7.3](/filings/0001193125-26-226804.md) | [7.6](/filings/0001193125-26-349309.md) |
| Shareholders' equity | $m | [(13.6)](/filings/0000950170-24-127033.md) | [(18.1)](/filings/0001193125-26-134813.md) | [(20.3)](/filings/0001193125-25-282905.md) | [(16.6)](/filings/0001193125-25-282905.md) | [(17.6)](/filings/0001193125-25-282905.md) | [(19.6)](/filings/0001193125-26-349309.md) | [(21.8)](/filings/0001193125-26-349309.md) | [(25.2)](/filings/0001193125-26-349309.md) | [(13.5)](/filings/0001193125-25-282905.md) | [(14.2)](/filings/0001193125-26-349309.md) | [(12.7)](/filings/0001193125-26-349309.md) | [(14.0)](/filings/0001193125-26-349309.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(4,209) d](/filings/0000950170-24-127033.md) | [(3,036) d](/filings/0000950170-25-041379.md) | [(2,542)](/filings/0000950170-25-072789.md) | [(2,291) d](/filings/0000950170-25-108894.md) | [(2,995) d](/filings/0001193125-25-282905.md) | [(1,728) d](/filings/0001193125-26-134813.md) | [(1,341)](/filings/0001193125-26-226804.md) | [(1,569) d](/filings/0001193125-26-349309.md) | [(941) d](/filings/0001193125-25-282905.md) | [(2,074) d](/filings/0001193125-26-134813.md) | [(1,733)](/filings/0001193125-26-226804.md) | [(2,083) d](/filings/0001193125-26-349309.md) |
| Capital expenditure | $k | [23.0 d](/filings/0000950170-24-127033.md) | [0.0 d](/filings/0000950170-25-041379.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [33.8](/filings/0000950170-23-063851.md) | [34.0](/filings/0000950170-24-059081.md) | [34.4](/filings/0000950170-24-096142.md) | [34.5](/filings/0000950170-24-127033.md) | [3.5](/filings/0000950170-25-072789.md) | [3.7](/filings/0000950170-25-108894.md) | [4.0](/filings/0001193125-25-282905.md) | [4.0](/filings/0001193125-26-226804.md) | [4.0](/filings/0001193125-26-349309.md) | [4.4](/filings/0001193125-25-282905.md) | [4.8](/filings/0001193125-26-226804.md) | [5.0](/filings/0001193125-26-349309.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 5,103,002 at 2026-08-11, from the cover of the [10-Q filed 2026-08-13](/filings/0001193125-26-349309.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.